Pharmaceutical

AHA 2024: lerodalcibep provides promising results in open-label extension trial, LIBERATE-OLE

At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving lerodalcibep.

Nov 19, 2024 - 06:00
AHA 2024: lerodalcibep provides promising results in open-label extension trial, LIBERATE-OLE
At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving lerodalcibep.
Read the original article

Tags:

Previous Article

AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults

Next Article

EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

With cancer expected to surge 77% worldwide by 2050, an oncologist weighs in on global disparities

With cancer expected to surge 77% worldwide by 2050, an...

Feb 5, 2024

ADC terminates Phase II trial for lymphoma therapy

ADC terminates Phase II trial for lymphoma therapy

Jul 21, 2023

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

May 15, 2024